The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Published

Journal Article

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.

Full Text

Duke Authors

Cited Authors

  • Wilke, RA; Ramsey, LB; Johnson, SG; Maxwell, WD; McLeod, HL; Voora, D; Krauss, RM; Roden, DM; Feng, Q; Cooper-Dehoff, RM; Gong, L; Klein, TE; Wadelius, M; Niemi, M; Clinical Pharmacogenomics Implementation Consortium (CPIC),

Published Date

  • July 2012

Published In

Volume / Issue

  • 92 / 1

Start / End Page

  • 112 - 117

PubMed ID

  • 22617227

Pubmed Central ID

  • 22617227

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

International Standard Serial Number (ISSN)

  • 0009-9236

Digital Object Identifier (DOI)

  • 10.1038/clpt.2012.57

Language

  • eng